Today: 21 May 2026
Netflix stock dips as UK antitrust pressure mounts on Warner bid and Senate hearing nears
27 January 2026
2 mins read

Netflix stock dips as UK antitrust pressure mounts on Warner bid and Senate hearing nears

NEW YORK, Jan 27, 2026, 11:00 EST — Regular session

  • Shares of Netflix slipped roughly 1.2% in late morning deals amid growing political scrutiny over its Warner bid
  • UK politicians pressed the CMA to launch a full competition review, intensifying the growing regulatory pressure
  • A Wall Street analyst’s upgrade yesterday provided only modest backing, as deal risk continues to weigh on sentiment

Netflix shares dipped Tuesday as British lawmakers called on the UK’s competition authority to scrutinize the streamer’s proposed Warner Bros Discovery deal. The dispute is increasingly taking on a political edge, overshadowing financial concerns.

Netflix slipped 1.2% to $84.70 by 11:00 a.m. EST, surrendering earlier gains as investors questioned if the deal’s timeline is dragging out once more.

Why this matters now: the stock has turned into a stand-in for regulatory risk linked to the Warner bid, as investors weigh the chances the deal will face drawn-out reviews across multiple jurisdictions, potentially lasting months and demanding concessions.

Any forced delay sparks follow-up concerns — financing, management attention, and whether Netflix might have to cough up more to secure the deal if competing bids and political hurdles continue to swirl.

Over a dozen British politicians and former policymakers have urged the Competition and Markets Authority to conduct a full review, warning the deal would “cement an already dominant player” in TV streaming and risk “a substantial lessening of competition,” Reuters reported. The letter, dated Jan. 23, was addressed to CMA chief executive Sarah Cardell, according to Reuters. Source

The CMA declined to speculate on cases not under formal investigation, Reuters reported. Netflix and Warner did not immediately reply to Reuters’ requests for comment.

Senator Mike Lee, chair of the Senate Judiciary antitrust subcommittee, has zeroed in on the deal and set a hearing for Feb. 3, The Capitol Forum reports. Lee cautioned that the review process could be “misused” to bog down a competitor, dubbing the tactic a “killer non-acquisition”—a merger attempt that damages a rival even if it never goes through. Source

Warner’s camp fired back. A Warner Bros spokesperson commended Netflix for its “hard” efforts to finalize the deal and emphasized that Warner “continues to operate as a fully independent company,” The Capitol Forum reported.

Just a day earlier, Phillip Securities analyst Helena Wang raised Netflix’s rating from “Sell” to “Accumulate,” boosting her price target to $100. She highlighted Netflix’s “clear leadership” in video-on-demand and its strong pricing power, according to a note cited by TheFly. (An “Accumulate” rating suggests investors should add shares gradually rather than buy aggressively.) Source

Warner Bros Discovery shares held steady at $28.24. Meanwhile, rival bidder Paramount Skydance dropped 3.2%, closing at $11.51, highlighting how fast deal chatter ripples through the sector.

The risk is straightforward: should regulators launch deeper investigations or signal strong resistance, Netflix’s bid might come with strings attached that dilute its strategic value — or drag out the process, leaving the stock driven more by news than by earnings.

Investors are turning to the Feb. 3 Senate hearing highlighted by The Capitol Forum. Signals from UK regulators on whether the CMA will launch a formal review could shape the next move for NFLX.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps
Previous Story

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom
Next Story

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom

Go toTop